TACIT: Tau And Connectomics In TES Study
Study Details
Study Description
Brief Summary
This pilot study aims to assess if participants that meet the criteria for a TES diagnosis have a specific tau deposition profile on PET scanning using the PET tau binding ligand - [18F] PI-2620. It is hoped this study will highlight potential diagnostic tests of TES diagnosis, the in-life correlate of CTE.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: [18F] PI-2620 PET Tau Ligand Active Agent Participants receive dose of active agent [18F] PI-2620 PET Tau Ligand during dynamic PET scan acquisition |
Radiation: [18F] PI-2620 Tau Ligand
Tau binding ligand
|
Outcome Measures
Primary Outcome Measures
- Detection of Tau protein 3R and 4R isoforms in patients who meet the Traumatic Encephalopathy Syndrome (TES) criteria, as defined by the National Institute of Neurological Disorders and Stroke. [2 weeks]
Participants are either Tau positive or Tau negative, determined by the PET scan
Secondary Outcome Measures
- Detect disease anomalies on MRI which correlated with brain region tau deposition [2 weeks]
Regional Tau load on PET scan compared with MRI
- Compare PET tau imaging PI-2620 results in TES to prior studies in Alzheimer's disease using the same ligand [2 weeks]
By comparing PET data against reference ranges
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The participant must have full capacity to understand the purpose and risks of the study to provide informed consent.
-
All participants must be between 40 to 70 years of age.
-
Must meet the Traumatic Encephalopathy Syndrome criteria as defined by the National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome, Katz. D, et. al. Neurology, 2021.
-
Participants must demonstrate that they have a cognitive decline, evident by performance on neuropsychological testing.
-
Standard of care blood screening within 12 months of consent to the study to exclude other medical conditions which may cause cognitive decline, such as heavy metal toxicology.
-
A PET scan within 6 months of consent to the study that is not consistent with Alzheimer's disease.
-
Participants must consent to undertake Positron Emission Tomography (PET) with intravenous [18F] PI-2620 PET tracer ligand.
-
Participants must be able to lie still, on their back for up to 60 minutes for the scans.
-
Participants must not have any metal in their bodies e.g. pacemakers, aneurysm clips which are contraindications of MRI.
-
Participants must consent to the use of their medical records and medical history, including but not limited to pathology results, previous imaging results and neuropsychology results
Exclusion Criteria:
-
Participants will be excluded if they do not meet all the inclusion criteria.
-
Participants must not be diagnosed with or suspected to be suffering from any other neurodegenerative disease, or cerebral disease affecting cognition as identified by results of neuropsychological evaluation or neurologist consultation.
-
Participants will be excluded if Staff at Macquarie Medical Imaging determine that the participant is not suitable for imaging, for any reason.
-
Participants will be excluded if they have kidney and/or liver dysfunction as diagnosed by a doctor
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Macquarie Medical Imaging | Macquarie Park | New South Wales | Australia | 2109 |
Sponsors and Collaborators
- Macquarie University, Australia
- Omniscient Neurotechnology
- Life Molecular Imaging GmbH
Investigators
- Principal Investigator: Rowena Mobbs, MBBS, PhD, MQ Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CNTES01